Early movers: MS, HAL, TUP, DIS, PNRA, MSFT, ISRG, FOXA, GE, UL & more

Check out which companies are making headlines before the bell:

Morgan Stanley — The bank earned 75 cents per share for the second quarter, beating forecasts of 59 cents a share. Revenue was also above estimates, with Morgan Stanley helped by better-than-expected results in investment banking and fixed income.

Halliburton — The oilfield services provider posted a loss of 14 cents per share, with results hurt by the breakup fee for its failed deal to buy Baker Hughes, but that was smaller than the 19 cent a share loss analysts were expecting. Halliburton also saw revenue come in above Street forecasts.

Tupperware — The household products maker came in six cents a share above estimates, with adjusted quarterly profit of $1.16 per share. Revenue was also above estimates. Tupperware saw strong results during the quarter in many of its international markets.

Walt Disney — Stifel downgraded Disney to "hold" from buy" on what the firm labels a valuation call.

Panera Bread — RBC began coverage on the restaurant chain's stock with an "outperform" rating, saying the stock has 20 percent upside as the company benefits from the payoff of a multi-year investment cycle.

Microsoft — Microsoft reported adjusted earnings of 69 cents per share for its latest quarter, 11 cents a share above estimates. Revenue also beat forecasts. Of particular note to investors: a seven percent jump in cloud-based business, a key focus for the software giant.

Intuitive Surgical — The company reported profit of $5.62 per share for the second quarter, 65 cents a share above estimates, thanks to higher sales of its da Vinci robotic surgical systems and an increased number of procedures.

21st Century Fox — Fox is nearing a decision on the future of Fox News chief Roger Ailes, with sources telling CNBC the decision is likely to result in Ailes' departure. The company is still in the process of conducting a review following a sexual harassment lawsuit filed by former Fox anchor Gretchen Carlson.

United Continental — United reported adjusted quarterly profit of $2.61 per share, five cents a share above estimates. Revenue was just slightly above analysts' projections. The beat came despite the negative impact of a stronger dollar, increased industry capacity, and pricing pressures. The airline also unveiled a $2 billion stock buyback program.

Cintas — The uniform maker earned an adjusted $1.08 per share for its latest quarter, eight cents a share above estimates. Revenue also topped forecasts. The company also gave a strong forecast for the full year, as both its uniform and facilities services businesses performed well.

General Electric — GE struck a partnership with China's Huawei Technologies to develop productivity-enhancing "smart machines." The announcement came as GE launched an $11 million digital facility in Shanghai.

Unilever — Unilever bought Dollar Shave Club in an effort to challenge Procter & Gamble's Gillette brand. Terms were not disclosed, but Fortune reported that Unilever would pay $1 billion in cash for Dollar Shave Club.

Chesapeake Energy — Chesapeake is being sued by investors, who accuse Chesapeake of conspiring to depress market prices for certain oil and natural gas leases and say they lost more than $10 million as a result. Chesapeake said it disagreed with the assertions of those investors and would address them "in the appropriate forum."

AstraZeneca — AstraZeneca lost its bid for a temporary restraining order, aimed at blocking approval of new U.S. generic versions of the drugmaker's cholesterol treatment Crestor. Novartis and Mylan are among the companies preparing to launch generic versions of the best-selling drug.

SAP — SAP reported a 73 percent jump in profit for its second quarter compared to a year ago, with the business software provider's results boosted by growth in its cloud business and a reduction in restructuring costs.

Valeant Pharmaceuticals — Valeant received Food and Drug Administration approval for the tablet form of its "Relistor" drug, which treats certain types of constipation. An injectable version has been on the market since 2008.

Questions? Comments? Email us at marketinsider@cnbc.com